Medical Device News Magazine

Kubota Vision Demonstrates 3D Imaging Capabilities Using AI on PBOS

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Kubota Vision, a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company demonstrated 3D imaging capabilities using artificial intelligence (AI) on their Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device.*1

Kubota Vision completed a successful clinical study in October 2018 that demonstrated the PBOS could detect thinning and thickening of the human retina over time, when compared to results from an established commercial OCT device. (See October 28, 2018 press release titled “Acucela Completes PBOS Clinical Study and Validates Concept.”)

A commercial OCT device is large and expensive, and mainly used at large eye clinics/centers and laboratories; however, our PBOS is a home-based, patient-friendly, ophthalmic self-monitoring miniature OCT device designed to detect disease progression. It uses network connectivity and cloud-based technologies to share images and alert patients and their physicians of disease progression and re-treatment needs, without requiring physician office visits.

The first fully-functional, working PBOS prototypes have been completed, and the company is currently in the process of further improving the software including 3D imaging capabilities. The 3D imaging assists in the detection of fluid buildup within and under the retina of the eye. Kubota Vision will continue advancing this program and seeking partnership opportunities for commercialization.

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision, stated, “We are excited to share this great news that our PBOS demonstrated 3D imaging capabilities using AI via internet data transfer. We will continue working on its improvement as well as gathering data to become a big data-driven company in ophthalmology. Our goal is to improve the quality of how we treat patients with ophthalmic diseases and make it available globally to people in need.”


*1 OCT (Optical Coherence Tomography) is a non-invasive tool that uses light waves to take cross-section pictures of the retina.

*2 mHealth refers to the usage of mobile communications technology and devices to enhance access to healthcare information, improve distribution of routine and emergency health services, and provide diagnostic services.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.